The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Seeking Alpha
The acquisition provides insurance against competitive threats to Voxzogo, BMRN's key growth driver facing pressure from Ascendis and BridgeBio pipeline advances. The deal is initially slightly dilutive to 2026 non-GAAP EPS but is expected to be substantially accretive from 2027 as synergies and expansion opportunities materialize. An analysis around BioMarin Pharmaceuticals follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » iQoncept/iStock via Getty Images Shares of rare disease concern BioMarin Pharmaceuticals Inc. ( BMRN initially rallied nicely after announcing its intention to acquire model portfolio holding Amicus Therapeutics ( FOLD for $4.8 billion on December 19th. The acquisition delivers two rare disease More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to ShareholdersBusiness Wire
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.MarketBeat
- Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 2/2/26 - Form DEFM14A
- 1/26/26 - Form DEFA14A
- 1/26/26 - Form 8-K
- FOLD's page on the SEC website